Pepgen (PEPG) closed at $3.83 on November 18, 2026, down 1.3% from the previous close, on volume of 3,256,611 shares (30-day average 5,697,742).
Data as of November 18, 2026.
18-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 10, 2026 | Call Spread | 20-Nov-265 : 6 C | 2,002 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 17, 2026. See the largest for 5, 30, 60 and 90 days
Capricor, Regenxbio among gainers as White House pulls Trump’s FDA pick
Seeking Alpha News (Wed, 18-Nov 9:06 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), IN8bio (INAB)
TipRanks (Mon, 16-Nov 12:00 PM ET)
PepGen Announces Pricing of $125 Million Public Offering
Business Wire (Wed, 11-Nov 10:22 PM ET)
PepGen Announces Proposed $125.0 Million Public Offering of Common Stock
Business Wire (Tue, 10-Nov 4:23 PM ET)
Market Chameleon (Tue, 10-Nov 4:52 AM ET)
PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Business Wire (Tue, 10-Nov 7:05 AM ET)
Business Wire (Tue, 10-Nov 7:01 AM ET)
PepGen Advances to Highest Dose in FREEDOM2-DM1 Study as Safety Profile Supports Next Steps
Market Chameleon (Thu, 6-Aug 7:17 AM ET)
PepGen’s $100 Million Offering Signals Bold Clinical Ambitions and Liquidity Boost
Market Chameleon (Thu, 25-Sep 5:53 AM ET)
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
Pepgen trades on the NASDAQ stock market under the symbol PEPG.
As of November 18, 2026, PEPG stock price declined to $3.83 with 3,256,611 million shares trading.
PEPG has a beta of 0.58, meaning it tends to be less sensitive to market movements. PEPG has a correlation of 0.00 to the broad based SPY ETF.
PEPG has a market cap of $265.26 million. This is considered a Small Cap stock.
In the last 3 years, PEPG traded as high as $19.30 and as low as $.88.
The top ETF exchange traded funds that PEPG belongs to (by Net Assets): VTI, IBB, VXF, IWC, BUSM.
PEPG has underperformed the market in the last year with a return of -28.4%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in PEPG shares. However, PEPG has outperformed the market in the last 3 month and 2 week periods, returning +26.0% and +55.7%, while SPY returned -5.3% and -3.2%, respectively. This indicates PEPG has been having a stronger performance recently.
PEPG support price is $3.64 and resistance is $4.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PEPG shares will trade within this expected range on the day.